Dossier assessment
Melatonin (sleep disorders in children and adolescents with autism spectrum disorder and/or Smith-Magenis syndrome) - Addendum to Commission A19-04
Report documents
-
Addendum
Melatonin (sleep disorders in children and adolescents with autism spectrum disorder and/or Smith-Magenis syndrome) - Addendum to Commission A19-04
Dossier assessment
Insomnia in children and adolescents with Autism Spectrum Disorder and/or Smith-Magenis syndrome, where sleep hygiene measures have been insufficient
Conclusion of dossier assessment A19-04 unchanged
Additional information
Federal Joint Committee (G-BA)
17 October 2024: The G-BA’s decision of 4 July 2019 was cancelled.
G-BA documents on this decision
Project details
- Project no.
- A19-47
- Commission
- Commission awarded on 27.05.2019 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Digestion, metabolism and hormones
- Note
-
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
Connected Projects
-
Dossier assessment
Melatonin (sleep disorders) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed